Ticker Hub
JNJ — AI Analysis & Sentiment
13 recent AI-generated analyses for JNJ. Sentiment and confidence insights updated continuously.
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
J&J's positive pivotal data for RYBREVANT FASPRO in advanced head and neck cancer and subsequent FDA submission strengthens its oncology pipeline. ...
May 31, 2026Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
Johnson & Johnson's latest Phase 3 clinical trial results for ERLEADA in prostate cancer are highly positive, showing significant patient benefit a...
May 31, 2026New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
Johnson & Johnson has announced robust Phase 3 data for TECVAYLI®, showing superior survival outcomes in multiple myeloma, which will support its e...
May 29, 2026FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
Johnson & Johnson received FDA approval to expand TREMFYA's label, highlighting its ability to inhibit joint damage in psoriatic arthritis. This st...
May 28, 2026Johnson & Johnson study shows TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate efficacy in perianal fistulizing Crohn's disease
Johnson & Johnson's positive Phase 3 results for TREMFYA in Crohn's disease validate the drug's expanding potential. This strengthens JNJ's diversi...
May 5, 2026ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
Positive one-year clinical trial results for ICOTYDE enhance its competitive profile and long-term sales potential within Johnson & Johnson's pharm...
Mar 28, 2026FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
Johnson & Johnson received FDA approval for ICOTYDE™ (icotrokinra), a new oral treatment for moderate-to-severe plaque psoriasis. This matters econ...
Mar 18, 2026Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
Johnson & Johnson's early clinical trial results for Erda-iDRS in bladder cancer are promising, showing high response rates and durability. This st...
Mar 13, 2026Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients
The FDA approval for TECNIS PureSee IOL enhances J&J's MedTech offerings, supporting future growth and strengthening its competitive standing in a ...
Mar 12, 2026Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Johnson & Johnson's FDA approval for TECVAYLI® and DARZALEX FASPRO® introduces a new treatment option for relapsed/refractory multiple myeloma, enh...
Mar 5, 2026Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)
Johnson & Johnson announced that nipocalimab received FDA Fast Track designation for systemic lupus erythematosus. This is important because it cou...
Mar 3, 2026RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
The FDA's Breakthrough Therapy Designation for RYBREVANT FASPRO in head and neck cancer is a significant positive step, accelerating development an...
Feb 18, 2026FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
The FDA approval of J&J's once-a-month EGFR therapy provides a significant competitive advantage in oncology. The market has not yet priced in this...
Feb 17, 2026